BioSpace News Archive

Teligent, Inc., a New Jersey based specialty generic pharmaceutical company, will be presenting at Jefferies Global Healthcare Conference.

Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) today announced that it will hold an investor conference call on Friday November 29, 2019 at 9:30 am.

ProQR Therapeutics N.V., a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, announced that Company management will present at upcoming investor conferences

Revenue includes sales of infectious disease, mosquito abatement products and AgBio primer design services

Precision BioSciences, Inc., a genome editing company dedicated to improving life through the application of its pioneering, proprietary ARCUS® platform, announced that Kevin J. Buehler, former CEO of Alcon Laboratories, has been appointed to its Board of Directors, which took effect following the company’s third quarter board meeting held on November 8, 2019..

Key Scientific Publication in Obstetrics & Gynecology Shows Sera is the Leading Authority in Assessing Preterm Birth Risk

ZyVersa Therapeutics, Inc. (ZyVersa), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment of inflammatory and renal diseases, is pleased to announce that Stephen C. Glover, ZyVersa’s Co-Founder, Chief Executive Officer, and President, is an invited speaker at the Stifel 2019 Healthcare Conference

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Dean Schorno, the company’s chief financial officer, is scheduled to present a company overview at the Jefferies 2019 London Healthcare Conference on Thursday, November 21, 2019 at 4:40pm GMT.

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today provided an update on the status of its development programs.

Novus Therapeutics, Inc. (NASDAQ: NVUS), a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat (ENT), today announced financial results for the quarter ended September 30, 2019.